SciELO - Scientific Electronic Library Online

 
vol.28 número1Utilidad de los anticuerpos anti-C1q y anti-nucleosomas en el lupus eritematoso sistémico y la nefritis lúpica en el suroccidente colombianoFrecuencia de anergia en un grupo de pacientes con artritis reumatoide y terapia inmunosupresora índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Colombiana de Reumatología

versión impresa ISSN 0121-8123

Resumen

MACHADO-DUQUE, Manuel E. et al. Patterns of anti-gout drug use in a Colombian population: 2016. Rev.Colomb.Reumatol. [online]. 2021, vol.28, n.1, pp.11-15.  Epub 20-Sep-2021. ISSN 0121-8123.  https://doi.org/10.1016/j.rcreu.2020.05.020.

Objective:

To identify the clinical characteristics of patients with gout, and the prescription patterns of anti-gout medications in Colombia.

Methods:

Cross-sectional study, that analysed the data from 310 medical records of patients treated in the last quarter of 2016, and who received an anti-gout medication. Sociodemographic, clinical, pharmacological, comorbidities, and paraclinical variables were identified. For each anti-gout drug used, it was determined whether the use was in accordance with Federal Drug Administration (FDA) approved recommendations. Descriptive, bivariate and multivariate analyses were performed.

Results:

Patients from 14 different cities in Colombia were evaluated, with a male predominance of 70.3% (n = 218) and a median age of 64 years (RIC: 26-94 years). The most frequently used anti-gout medication was allopurinol (n = 255; 82.3%), followed by colchicine (n = 54; 17.4%). The main diagnoses found as an indication were: hyperuricaemia (n=181, 58.4%), gout (n = 34; 11.0%), and gouty arthritis (n = 28; 9.0%). Almost three-quarters (74.5%; n = 231) of the prescriptions had an approved use according to the FDA, especially allopurinol in the management of gout and hyperuricaemia, while colchicine was found to be used in unapproved indications (n = 44, 81.4%). The most frequent comorbidities were hypertension (68.4%) and dyslipidaemia (55.8%).

Conclusions:

Patients with gout who are under pharmacological treatment have a high frequency of cardiovascular comorbidities. They were being treated with allopurinol for long-term prevention, while a smaller proportion received colchicine, which is often used for indications not approved by regulatory agencies.

Palabras clave : Gout; Gout suppressants; Allopurinol; Colchicine; Pharmaco-epidemiology.

        · resumen en Español     · texto en Español     · Español ( pdf )